|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
gptkb:physician
|
|
gptkbp:approvalYear
|
2009
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:Crohn's_disease
gptkb:psoriatic_arthritis
ulcerative colitis
plaque psoriasis
|
|
gptkbp:ATCCode
|
L04AC05
|
|
gptkbp:CASNumber
|
815610-63-0
|
|
gptkbp:contraindication
|
hypersensitivity to ustekinumab
|
|
gptkbp:cost
|
high
|
|
gptkbp:drugClass
|
gptkb:monoclonal_antibody
|
|
gptkbp:form
|
solution for injection
concentrate for solution for infusion
|
|
gptkbp:genericName
|
gptkb:ustekinumab
|
|
gptkbp:halfLife
|
15-45 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Stelara
|
|
gptkbp:indication
|
active psoriatic arthritis
moderate to severe plaque psoriasis
moderately to severely active Crohn's disease
moderately to severely active ulcerative colitis
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:manufacturer
|
gptkb:Janssen_Biotech
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
interleukin-12 inhibitor
interleukin-23 inhibitor
|
|
gptkbp:monitoredParameter
|
malignancy
liver function
signs of infection
tuberculosis screening
|
|
gptkbp:pregnancyCategory
|
Category B (US)
|
|
gptkbp:prescriptionRequired
|
https://www.stelarainfo.com/
|
|
gptkbp:routeOfAdministration
|
intravenous infusion
subcutaneous injection
|
|
gptkbp:sideEffect
|
nausea
diarrhea
fatigue
headache
back pain
injection site reactions
upper respiratory tract infection
|
|
gptkbp:UNII
|
6J8J2873RU
|
|
gptkbp:bfsParent
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
5
|